Sequencing Reagents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Sequencing Reagents Market is projected to grow from USD 9.57 Billion in 2025 to USD 17.46 Billion by 2031, registering a CAGR of 10.54%. These reagents, comprising essential enzymes, chemical kits, and consumables, are critical for library preparation and nucleic acid analysis in research and clinical environments. The market is primarily driven by the rising prevalence of chronic diseases and the subsequent need for precision medicine reliant on accurate genomic profiling. For instance, the American Cancer Society estimates that 2,041,910 new cancer cases will occur in the United States in 2025, highlighting the urgent need for advanced diagnostic capabilities. This increasing disease burden mandates the continuous procurement of high-quality reagents for targeted therapy selection and mutation detection.

However, market expansion is hindered by the significant capital investment necessary to establish sequencing infrastructure. Many smaller laboratories and institutions, particularly in emerging economies, face difficulties with the high costs associated with acquiring and maintaining advanced sequencing platforms. This financial barrier directly limits their ability to purchase recurring reagent supplies, effectively restricting the addressable market. Consequently, the high cost of entry slows the global adoption of advanced sequencing technologies in resource-limited settings, reducing the overall potential for reagent consumption in these regions.

Market Drivers

Technological advancements in next-generation sequencing platforms are a major force propelling the Global Sequencing Reagents Market. The deployment of high-throughput systems has lowered sequencing costs while increasing data output, creating a need for a larger volume of consumable kits for flow cell usage and library preparation. As laboratories shift to these high-capacity instruments to maximize efficiency, recurring revenue from the associated reagents has grown. For example, Oxford Nanopore Technologies reported in September 2025 that revenue from its PromethION product range rose to £51.1 million for the first half of the year. This growth illustrates how platform innovation stimulates the continuous consumption of specialized chemical reagents required for large-scale genomic operations.

Simultaneously, a surge in government initiatives and genomics research funding is accelerating market demand by facilitating large-scale population studies. Public and private investments are increasingly targeting pangenome references and precision medicine programs, which depend heavily on extensive sequencing workflows. In March 2025, Genome Canada launched the Canadian Precision Health Initiative with an $81 million investment to build a diverse genomic data resource. Additionally, News-Medical.Net reported in 2025 that Washington University School of Medicine received $14 million to renew the Human Pangenome Reference Sequencing Project. Such financial support allows research centers to procure the necessary consumables for thousands of samples, ensuring sustained market growth.

Market Challenges

The substantial capital investment required to establish sequencing infrastructure acts as a significant barrier to the expansion of the Global Sequencing Reagents Market. The high costs associated with acquiring genomic platforms effectively exclude smaller laboratories and research institutions in resource-constrained regions from entering the sector. Since reagent consumption is intrinsically linked to the installed base of sequencing instruments, the inability of these entities to surmount initial financial hurdles directly limits the volume of recurring sales. Without the budget to procure the necessary hardware, potential customers cannot generate demand for the associated chemical kits and consumables, thereby restricting the total addressable market.

This economic pressure is further exacerbated by contractions in research funding, which is a critical lifeline for capital equipment procurement in clinical and academic sectors. According to the Association of American Medical Colleges, the National Institutes of Health committed approximately $5 billion less in research grants to United States institutions in 2025 compared to the previous year. Such significant reductions in available capital constrain the purchasing power of laboratories, compelling them to defer infrastructure upgrades or expansion. Consequently, this stagnation in platform adoption creates a downstream bottleneck that severely hampers volume growth in the sequencing reagents sector.

Market Trends

The market is witnessing a decisive surge in demand for spatial genomics and single-cell consumables, driven by the critical need to resolve cellular heterogeneity often obscured by bulk sequencing. Researchers are increasingly adopting complex reagent kits capable of mapping gene expression directly to tissue architecture or barcoding individual cells, workflows that command a significantly higher price point per sample compared to standard library preparation. This shift toward high-resolution biological analysis is sustaining revenue growth in the reagents sector, even as capital equipment sales face volatility. For instance, 10x Genomics reported in January 2025 that consumables revenue reached approximately $493.4 million for the full year 2024, representing 3% growth over the prior year despite a challenging instrument sales environment.

Simultaneously, the development of specialized reagents for oncology profiling and liquid biopsy is creating a robust, high-volume sub-segment. Laboratories are actively procuring advanced chemistry sets designed for the ultra-sensitive detection of methylation patterns and circulating tumor DNA (ctDNA), which are essential for therapy monitoring and non-invasive cancer screening. These precision diagnostic workflows require highly optimized enrichment panels and enzymes to ensure accuracy, significantly increasing the frequency of recurring reagent orders from clinical providers. Underscoring this trend, Guardant Health reported in February 2025 that oncology clinical test volumes grew by 20% year-over-year to approximately 206,700 tests for the full year 2024, directly fueling the consumption of these specialized molecular diagnostics consumables.

Key Players Profiled in the Sequencing Reagents Market

• Thermo Fisher Scientific, Inc.
• Abzena Ltd.
• Illumina, Inc.
• QIAGEN N.V.
• Pacific Biosciences of California, Inc.
• F. Hoffmann-La Roche Ltd.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• Fluidigm Corporation
• Integrated DNA Technologies, Inc.

Report Scope

In this report, the Global Sequencing Reagents Market has been segmented into the following categories:

Sequencing Reagents Market, by Technology:

• Sanger Sequencing
• Next-Generation Sequencing
• Third Generation Sequencing

Sequencing Reagents Market, by Type:

• Library Kits
• Template Kits
• Control Kits
• Sequencing Kits
• Others

Sequencing Reagents Market, by Application:

• Oncology
• Reproductive Health
• Clinical Investigation
• Agrigenomics & Forensics
• Others

Sequencing Reagents Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sequencing Reagents Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.